IRMD
Iradimed Co
82.50$
+0.4%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 95.1% | 96.3% | 91.9% | 90.0% | 91.9% | 88.4% | 89.7% | 92.0% | 90.6% | 82.5% | 76.5% | 74.7% | |
| 40.6% | 55.0% | 47.6% | 46.7% | 57.9% | 65.2% | 70.5% | 74.8% | 67.8% | 54.0% | 53.1% | 47.0% | |
| 74.5% | 76.5% | 69.0% | 67.5% | 71.0% | 69.3% | 73.1% | 75.4% | 67.8% | 54.0% | 53.1% | 47.0% | |
| 8.4% | 11.0% | 10.2% | 9.7% | 8.7% | 10.9% | 6.4% | 6.2% | 15.5% | 13.3% | 10.7% | 12.6% | |
| 9.1% | 6.8% | 10.4% | 10.8% | 8.4% | 5.5% | 5.5% | 5.2% | 6.3% | 13.9% | 10.6% | 10.7% | |
| 3.4% | 2.6% | 3.9% | 4.8% | 3.9% | 3.1% | 3.0% | 5.5% | 2.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 1.1% | 0.5% | 2.5% | 2.3% | 1.7% | 1.3% | 1.4% | 1.3% | 2.4% | 2.7% | 3.2% | 3.1% | |
| 10.4% | 9.4% | 14.3% | 15.6% | 13.4% | 16.8% | 13.6% | 12.9% | 13.8% | 22.5% | 11.7% | 13.0% | |
| 9.8% | 8.2% | 9.8% | 10.5% | 9.7% | 8.8% | 6.9% | 8.2% | 10.0% | 17.7% | 8.7% | 9.4% | |
| 0.3% | 0.1% | 3.7% | 4.3% | 0.3% | 0.4% | 0.4% | 0.3% | 0.3% | 0.5% | 0.2% | – | |
| 2.7% | 2.9% | 3.0% | 1.7% | 1.6% | 1.5% | 0.9% | 0.9% | 2.1% | 2.0% | 1.9% | 1.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 89.6% | 90.6% | 85.7% | 84.4% | 86.6% | 83.2% | 86.4% | 87.1% | 86.2% | 77.5% | 88.3% | 87.0% | |
| 22.0% | 35.9% | 53.4% | 52.2% | 55.1% | 54.4% | 53.0% | 56.7% | 55.3% | 46.9% | 57.8% | 59.0% | |
| 43.8% | 35.6% | 32.2% | 30.0% | 25.0% | 18.4% | 17.5% | 15.2% | 14.8% | 13.8% | 13.0% | 11.8% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.